1. Effect of Immunosuppression on the Immune Response to SARS-CoV-2 Infection and Vaccination
- Author
-
Emma J. Leacy, Jia Wei Teh, Aoife M. O’Rourke, Gareth Brady, Siobhan Gargan, Niall Conlon, Jennifer Scott, Jean Dunne, Thomas Phelan, Matthew D. Griffin, Julie Power, Aoife Mooney, Aifric Naughton, Rachel Kiersey, Mary Gardiner, Caroline O’Brien, Ronan Mullan, Rachael Flood, Michael Clarkson, Liam Townsend, Michelle O’Shaughnessy, Adam H. Dyer, Barry Moran, Jean M. Fletcher, Lina Zgaga, and Mark A. Little
- Subjects
COVID-19 ,SARS-CoV-2 ,immunosuppression ,rituximab ,vaccine ,immune response ,Biology (General) ,QH301-705.5 ,Chemistry ,QD1-999 - Abstract
Immunosuppressive treatment in patients with rheumatic diseases can maintain disease remission but also increase risk of infection. Their response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination is frequently blunted. In this study we evaluated the effect of immunosuppression exposure on humoral and T cell immune responses to SARS-CoV-2 infection and vaccination in two distinct cohorts of patients; one during acute SARS-CoV-2 infection and 3 months later during convalescence, and another prior to SARS-CoV-2 vaccination, with follow up sampling 6 weeks after vaccination. Results were compared between rituximab-exposed (in previous 6 months), immunosuppression-exposed (in previous 3 months), and non-immunosuppressed groups. The immune cell phenotype was defined by flow cytometry and ELISA. Antigen specific T cell responses were estimated using a whole blood stimulation interferon-γ release assay. A focused post-vaccine assessment of rituximab-treated patients using high dimensional spectral cytometry was conducted. Acute SARS-CoV-2 infection was characterised by T cell lymphopenia, and a reduction in NK cells and naïve CD4 and CD8 cells, without any significant differences between immunosuppressed and non-immunosuppressed patient groups. Conversely, activated CD4 and CD8 cell counts increased in non-immunosuppressed patients with acute SARS-CoV-2 infection but this response was blunted in the presence of immunosuppression. In rituximab-treated patients, antigen-specific T cell responses were preserved in SARS-CoV-2 vaccination, but patients were unable to mount an appropriate humoral response.
- Published
- 2024
- Full Text
- View/download PDF